New Facebook Rules: A Challenge and an Opportunity for Pharma

Our latest white paper explores how pharmaceutical companies can manage and benefit from Facebook in light of Facebook’s new policy to require open comments. Yesterday, Pharmalot reported that some drugmakers may abandon Facebook if they can’t cope with the changes. They interviewed several drugmakers about their plans, including Sanofi and AstraZeneca, who acknowledge that they may walk away from Facebook if they cannot overcome concerns posed by the new policy. Continue reading